Antisense Oligonucleotide Therapy In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antisense oligonucleotides (ASOs) are short, synthetic single-stranded nucleic acid polymers (typically 15-25 nucleotides) designed to bind complementary mRNA sequences through Watson-Crick base pairing, thereby modulating gene expression at the post-transcriptional level. ASO therapy has emerged as one of the most clinically advanced genetic medicine platforms for [neurodegenerative diseases, with multiple FDA-approved drugs and a robust clinical pipeline [Bennett et al., 2019](https://doi.org/10.1146/annurev-pharmtox-010818-021756). The approval of nusinersen (Spinraza) for Spinal Muscular Atrophy in 2016 and tofersen (Qalsody) for [sod1-protein](/proteins/sod1-protein)-mutant [als](/diseases/amyotrophic-lateral-sclerosis) in 2023 has validated the ASO approach for CNS diseases, establishing a therapeutic paradigm that is now being extended to [alzheimers](/diseases/alzheimers-disease), [huntington-pathway](/mechanisms/huntington-pathway), [parkinsons](/diseases/parkinsons-disease), and [ftd](/diseases/frontotemporal-dementia) [Ludolph & Wiesenfarth, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC11752197/). [@ludolph2025]
Antisense Oligonucleotide Therapy In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antisense oligonucleotides (ASOs) are short, synthetic single-stranded nucleic acid polymers (typically 15-25 nucleotides) designed to bind complementary mRNA sequences through Watson-Crick base pairing, thereby modulating gene expression at the post-transcriptional level. ASO therapy has emerged as one of the most clinically advanced genetic medicine platforms for [neurodegenerative diseases, with multiple FDA-approved drugs and a robust clinical pipeline [Bennett et al., 2019](https://doi.org/10.1146/annurev-pharmtox-010818-021756). The approval of nusinersen (Spinraza) for Spinal Muscular Atrophy in 2016 and tofersen (Qalsody) for [sod1-protein](/proteins/sod1-protein)-mutant [als](/diseases/amyotrophic-lateral-sclerosis) in 2023 has validated the ASO approach for CNS diseases, establishing a therapeutic paradigm that is now being extended to [alzheimers](/diseases/alzheimers-disease), [huntington-pathway](/mechanisms/huntington-pathway), [parkinsons](/diseases/parkinsons-disease), and [ftd](/diseases/frontotemporal-dementia) [Ludolph & Wiesenfarth, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC11752197/). [@ludolph2025]
The most common ASO mechanism exploits endogenous RNase H1, an endonuclease that cleaves the RNA strand of DNA-RNA heteroduplexes. When a DNA-like ASO (typically a gapmer design with a central DNA segment flanked by chemically modified RNA wings) binds its target pre-mRNA or mRNA, RNase H1 recognizes the duplex and degrades the RNA, leading to potent and selective reduction of the target protein [Crooke et al., 2021](https://doi.org/10.1016/j.jbc.2021.100416). This mechanism is used by tofersen to degrade [sod1-protein](/proteins/sod1-protein) mRNA and by investigational ASOs targeting [mapt](/genes/mapt) ([tau](/proteins/tau), [snca](/genes/snca) ([alpha-synuclein](/proteins/alpha-synuclein), and [htt](/genes/htt) ([huntingtin). [@crooke2021]
ASOs can redirect pre-mRNA splicing by blocking or enhancing access of the spliceosome to specific splice sites or regulatory elements. Nusinersen, the landmark ASO for Spinal Muscular Atrophy, binds an intronic splicing silencer in the [smn2](/proteins/smn2-protein) gene, promoting inclusion of exon 7 and increasing production of functional survival motor neuron (SMN) protein [Finkel et al., 2017](https://doi.org/10.1056/NEJMoa1702752). Splice-switching ASOs are being explored for [c9orf72](/genes/c9orf72)-associated ALS/FTD to selectively degrade toxic repeat-containing transcripts while preserving normal [c9orf72](/genes/c9orf72) protein expression. [@miller2022]
Some ASOs function by physically blocking ribosomal scanning or translation initiation without triggering mRNA degradation. This approach is useful when partial reduction of protein levels is desired or when the target sequence is not amenable to RNase H-dependent cleavage. [@finkel2017]
The clinical success of ASOs depends on chemical modifications that enhance binding affinity, nuclease resistance, pharmacokinetics, and cellular uptake. [@tabrizi2022]
Phosphorothioate (PS) backbone modifications replace a non-bridging oxygen with sulfur, conferring nuclease resistance, promoting plasma protein binding for improved tissue distribution, and enabling RNase H1 activation [Eckstein, 2014](https://doi.org/10.1093/nar/gku202). All clinically approved CNS-targeting ASOs use PS backbones. [@mummery2023]
2'-O-Methoxyethyl (2'-MOE) modifications at the ribose 2' position dramatically increase binding affinity and metabolic stability. Tofersen and nusinersen both employ 2'-MOE gapmer and fully modified architectures, respectively. [@eckstein2014]
Locked nucleic acids (LNAs) contain a methylene bridge connecting the 2'-oxygen and 4'-carbon of the ribose, enforcing a C3'-endo conformation that provides the highest binding affinity of any nucleic acid modification. LNA-modified ASOs are in development for several neurodegeneration targets. [@geary2015]
Constrained ethyl (cEt) modifications offer a balance between binding affinity and hepatotoxicity risk, and are used in next-generation Ionis Pharmaceuticals ASO programs. [@biogen2025]
Tofersen, developed by Ionis Pharmaceuticals and Biogen, is a 2'-MOE gapmer ASO that degrades [sod1-protein](/proteins/sod1-protein) mRNA via RNase H1-mediated cleavage. It received FDA accelerated approval in April 2023 for [als](/diseases/amyotrophic-lateral-sclerosis) associated with SOD1 mutations, based on reduction of [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain ([neurofilament-light-chain](/proteins/neurofilament-light-chain), a biomarker of neuronal damage [Miller et al., 2022](https://doi.org/10.1056/NEJMoa2204705). The Phase 3 VALOR study and its open-label extension (OLE) with over 3.5 years of follow-up demonstrated that early tofersen initiation was associated with numerically slower decline in clinical function, respiratory capacity, and muscle strength, plus sustained [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl) reduction. Tofersen is administered intrathecally every 4 weeks following a loading dose period [Biogen, 2025](https://investors.biogen.com/news-releases/news-release-details/journal-american-medical-association-jama-neurology-publishes).
Nusinersen was the first ASO approved for a neurodegenerative condition (2016). By promoting exon 7 inclusion in [smn2](/proteins/smn2-protein) transcripts, it increases functional SMN protein production in [motor-neurons](/cell-types/motor-neurons). The ENDEAR trial demonstrated dramatic improvement in motor milestones in infants with Type 1 SMA, and long-term data show sustained benefit with continued intrathecal dosing [Finkel et al., 2017](https://doi.org/10.1056/NEJMoa1702752). Ionis and Biogen are developing salanersen, a next-generation ASO with improved potency that may enable once-yearly dosing.
The ASO program for [huntington-pathway](/mechanisms/huntington-pathway) has faced setbacks but remains active. Tominersen (formerly IONIS-HTTRx/RG6042), a non-allele-selective ASO targeting total [htt](/genes/htt) mRNA, was discontinued in Phase 3 (GENERATION HD1) due to worsening clinical outcomes at higher doses, suggesting that complete [huntingtin](/proteins/huntingtin) knockdown may be detrimental [Tabrizi et al., 2022](https://doi.org/10.1038/s41591-022-01977-2). Subsequent programs have pivoted to allele-selective approaches: Wave Life Sciences' WVE-003 and Roche's RG7234 target SNPs linked to the expanded CAG repeat allele, aiming to reduce mutant [huntingtin](/proteins/huntingtin) while preserving wild-type protein. These programs are in Phase 1/2 trials.
ASOs targeting [mapt](/genes/mapt) mRNA to reduce [tau](/proteins/tau) protein expression are in clinical development for [alzheimers](/diseases/alzheimers-disease) and other [tauopathies](/mechanisms/tauopathies). Ionis/Biogen's BIIB080 (IONIS-MAPTRx) has shown dose-dependent reduction of [tau](/proteins/tau) in cerebrospinal fluid in Phase 1/2 trials, with Phase 2 studies ongoing in mild AD and Progressive Supranuclear Palsy (PSP) [Mummery et al., 2023](https://doi.org/10.1038/s41591-023-02326-3). ASOs targeting [app](/genes/app) mRNA to reduce [amyloid-beta](/proteins/amyloid-beta) production are also in preclinical development.
ASOs targeting [snca](/genes/snca) mRNA to reduce [alpha-synuclein](/proteins/alpha-synuclein) expression are being developed for [parkinsons](/diseases/parkinsons-disease), [lewy-body-dementia](/diseases/lewy-body-dementia), and [msa](/diseases/msa-genetic-variants). Ionis' ION464 (BIIB101) entered Phase 1 trials for MSA, and [lrrk2](/proteins/lrrk2-protein)-targeting ASOs (BIIB094/ION859) are in Phase 2 for LRRK2-associated PD.
For [ftd](/diseases/frontotemporal-dementia) caused by [c9orf72](/genes/c9orf72) hexanucleotide repeat expansion — the most common genetic form of both ALS and FTD — ASOs targeting the expanded repeat transcripts aim to reduce toxic dipeptide repeat protein (DPR) production and RNA foci formation while preserving normal [c9orf72](/genes/c9orf72) protein function. Ionis/Biogen's afinersen (BIIB078) showed target engagement in Phase 1 but was discontinued; next-generation [c9orf72](/genes/c9orf72) ASOs are in development.
ASOs for CNS indications are administered intrathecally (via lumbar puncture) to achieve direct access to cerebrospinal fluid (CSF) and brain tissue. Following intrathecal injection, ASOs distribute broadly throughout the neuroaxis, accumulating in [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), and [oligodendrocytes](/cell-types/oligodendrocytes). The half-life of 2'-MOE ASOs in CNS tissue is approximately 4-6 months, enabling dosing intervals of 4-12 weeks after initial loading doses [Geary et al., 2015](https://doi.org/10.1016/j.nucmedbio.2014.12.012).
Key pharmacological considerations include: (1) regional distribution heterogeneity, with cortical regions receiving higher exposure than deeper structures like the [striatum](/brain-regions/striatum) or [brainstem](/brain-regions/brainstem); (2) cell-type-specific uptake differences, with [neurons](/entities/neurons) and [astrocytes](/cell-types/astrocytes) generally showing higher ASO accumulation than [oligodendrocytes](/cell-types/oligodendrocytes); and (3) the practical burden of repeated intrathecal injections, which drives interest in longer-acting formulations and alternative delivery routes.
The most common adverse effects of intrathecally delivered ASOs include post-lumbar puncture headache, back pain, and procedural complications. Class-specific toxicities include: (1) thrombocytopenia (particularly with heavily PS-modified ASOs); (2) hepatotoxicity (primarily with systemically administered ASOs); and (3) rare cases of communicating hydrocephalus observed with some intrathecally delivered ASOs. The tominersen HD trial highlighted the importance of dose optimization, as excessive target knockdown can be counterproductive when the target protein (e.g., wild-type [huntingtin](/genes/htt)) has essential normal functions.
ASOs targeting monogenic developmental and epileptic encephalopathies (DEEs) represent a rapidly advancing frontier, building directly on the success of nusinersen in spinal muscular atrophy. Unlike neurodegenerative diseases where ASOs aim to slow ongoing decline, NDE ASO programs seek to restore gene expression before irreversible developmental damage occurs.
[Dravet syndrome](/diseases/dravet-syndrome) — caused by loss-of-function variants in [SCN1A](/entities/scn1a) — is the most advanced NDE indication for ASO therapy. [Stoke Therapeutics](/companies/stoke-therapeutics) has developed STK-001, an allele-selective ASO that targets the nonsense-mediated decay (NMD) pathway to increase [SCN1A](/entities/scn1a) mRNA and restore Nav1.1 protein expression from the wild-type allele.
TANGO (Targeted Augmentation of Nuclear Gene Output) platform:
[Angelman syndrome](/diseases/angelman-syndrome) is caused by loss of maternal [UBE3A](/entities/ube3a) expression in neurons, where the paternal allele is silenced by an imprinting mechanism involving the UBE3A-ATS long non-coding RNA. [GeneTx Biotherapeutics](/companies/genetx-biotherapeutics) (an [Ultragenyx](/companies/ultragenyx) subsidiary) developed GTX-102, an ASO designed to bind UBE3A-ATS and block its repressive activity, thereby "unsilencing" the paternal [UBE3A](/entities/ube3a) allele.
Mechanism: ASO binds to the UBE3A-ATS transcript, sterically blocking its interaction with UBE3A pre-mRNA, which allows paternal UBE3A to be expressed in neurons.
| Program | Target | Indication | Route | Phase | Status |
|---------|--------|------------|-------|-------|--------|
| STK-001 (Stoke) | SCN1A | Dravet syndrome | Intrathecal | Phase 2 | BTD granted; data Q2-Q3 2026 |
| STK-002 (Stoke) | SCN1A | Dravet (adults) | Intrathecal | Phase 1 | Higher dose cohorts |
| GTX-102 (GeneTx) | UBE3A-ATS | Angelman syndrome | IV | Phase 2 | BLA expected Q3-Q4 2026 |
Unique challenges for NDE ASO development:
The study of Antisense Oligonucleotide Therapy In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving Antisense Oligonucleotide Therapy in Neurodegeneration discovered through SciDEX knowledge graph analysis: